Annual CFF
$25.85 M
-$144.62 M-84.83%
December 31, 2024
Summary
- As of March 12, 2025, PTGX annual cash flow from financing activities is $25.85 million, with the most recent change of -$144.62 million (-84.83%) on December 31, 2024.
- During the last 3 years, PTGX annual CFF has fallen by -$104.07 million (-80.10%).
- PTGX annual CFF is now -89.56% below its all-time high of $247.63 million, reached on December 31, 2020.
Performance
PTGX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$4.03 M
-$8.02 M-66.55%
December 31, 2024
Summary
- As of March 12, 2025, PTGX quarterly cash flow from financing activities is $4.03 million, with the most recent change of -$8.02 million (-66.55%) on December 31, 2024.
- Over the past year, PTGX quarterly CFF has dropped by -$8.02 million (-66.55%).
- PTGX quarterly CFF is now -96.83% below its all-time high of $126.98 million, reached on December 31, 2020.
Performance
PTGX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$25.85 M
+$3.50 M+15.68%
December 31, 2024
Summary
- As of March 12, 2025, PTGX TTM cash flow from financing activities is $25.85 million, with the most recent change of +$3.50 million (+15.68%) on December 31, 2024.
- Over the past year, PTGX TTM CFF has increased by +$3.50 million (+15.68%).
- PTGX TTM CFF is now -90.10% below its all-time high of $261.02 million, reached on June 30, 2021.
Performance
PTGX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
PTGX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -84.8% | -66.5% | +15.7% |
| 3 y3 years | -80.1% | -66.5% | +15.7% |
| 5 y5 years | -43.8% | -66.5% | +15.7% |
PTGX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -84.8% | +37.2% | -96.3% | +664.9% | -84.8% | +37.2% |
| 5 y | 5-year | -89.6% | +37.2% | -96.8% | +910.3% | -90.1% | +37.2% |
| alltime | all time | -89.6% | +187.2% | -96.8% | +573.1% | -90.1% | +7281.4% |
Protagonist Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $25.85 M(-84.8%) | $4.03 M(-66.6%) | $25.85 M(+15.7%) |
| Sep 2024 | - | $12.05 M(+368.5%) | $22.35 M(-51.0%) |
| Jun 2024 | - | $2.57 M(-64.3%) | $45.61 M(-69.8%) |
| Mar 2024 | - | $7.20 M(+1266.0%) | $151.21 M(-11.3%) |
| Dec 2023 | $170.48 M(+805.0%) | $527.00 K(-98.5%) | $170.48 M(-0.0%) |
| Sep 2023 | - | $35.31 M(-67.4%) | $170.50 M(+25.5%) |
| Jun 2023 | - | $108.17 M(+308.8%) | $135.87 M(+378.8%) |
| Mar 2023 | - | $26.46 M(+4685.4%) | $28.38 M(+50.6%) |
| Dec 2022 | $18.84 M(-85.5%) | $553.00 K(-18.7%) | $18.84 M(-7.9%) |
| Sep 2022 | - | $680.00 K(0.0%) | $20.46 M(-3.3%) |
| Jun 2022 | - | $680.00 K(-96.0%) | $21.16 M(-85.5%) |
| Mar 2022 | - | $16.93 M(+678.9%) | $145.87 M(+12.3%) |
| Dec 2021 | $129.92 M(-47.5%) | $2.17 M(+57.3%) | $129.92 M(-49.0%) |
| Sep 2021 | - | $1.38 M(-98.9%) | $254.73 M(-2.4%) |
| Jun 2021 | - | $125.39 M(>+9900.0%) | $261.02 M(+5.2%) |
| Mar 2021 | - | $979.00 K(-99.2%) | $248.21 M(+0.2%) |
| Dec 2020 | $247.63 M(+437.9%) | $126.98 M(+1555.8%) | $247.63 M(+89.9%) |
| Sep 2020 | - | $7.67 M(-93.2%) | $130.42 M(-11.9%) |
| Jun 2020 | - | $112.58 M(>+9900.0%) | $147.99 M(+221.4%) |
| Mar 2020 | - | $399.00 K(-95.9%) | $46.05 M(+0.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $46.04 M(+90.9%) | $9.78 M(-61.3%) | $46.04 M(+25.3%) |
| Sep 2019 | - | $25.24 M(+137.4%) | $36.74 M(+6.4%) |
| Jun 2019 | - | $10.63 M(+2625.6%) | $34.53 M(+44.0%) |
| Mar 2019 | - | $390.00 K(-18.6%) | $23.98 M(-0.6%) |
| Dec 2018 | $24.11 M(-63.2%) | $479.00 K(-97.9%) | $24.11 M(-72.8%) |
| Sep 2018 | - | $23.03 M(>+9900.0%) | $88.70 M(+35.0%) |
| Jun 2018 | - | $74.00 K(-86.0%) | $65.70 M(-0.0%) |
| Mar 2018 | - | $530.00 K(-99.2%) | $65.71 M(+0.2%) |
| Dec 2017 | $65.55 M(-38.3%) | $65.06 M(>+9900.0%) | $65.55 M(<-9900.0%) |
| Sep 2017 | - | $31.00 K(-64.4%) | -$360.00 K(-100.4%) |
| Jun 2017 | - | $87.00 K(-76.7%) | $84.89 M(+1.0%) |
| Mar 2017 | - | $374.00 K(-143.9%) | $84.05 M(-20.9%) |
| Dec 2016 | $106.31 M(+510.3%) | -$852.00 K(-101.0%) | $106.31 M(-0.8%) |
| Sep 2016 | - | $85.28 M(<-9900.0%) | $107.16 M(+173.1%) |
| Jun 2016 | - | -$750.00 K(-103.3%) | $39.24 M(-2.0%) |
| Mar 2016 | - | $22.63 M(>+9900.0%) | $40.05 M(+129.9%) |
| Dec 2015 | $17.42 M(+93.5%) | $0.00(-100.0%) | $17.42 M(0.0%) |
| Sep 2015 | - | $17.36 M(>+9900.0%) | $17.42 M(>+9900.0%) |
| Jun 2015 | - | $55.00 K(+2650.0%) | $57.00 K(+2750.0%) |
| Mar 2015 | - | $2000.00 | $2000.00 |
| Dec 2014 | $9.00 M | - | - |
FAQ
- What is Protagonist Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Protagonist Therapeutics?
- What is Protagonist Therapeutics annual CFF year-on-year change?
- What is Protagonist Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Protagonist Therapeutics?
- What is Protagonist Therapeutics quarterly CFF year-on-year change?
- What is Protagonist Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Protagonist Therapeutics?
- What is Protagonist Therapeutics TTM CFF year-on-year change?
What is Protagonist Therapeutics annual cash flow from financing activities?
The current annual CFF of PTGX is $25.85 M
What is the all time high annual CFF for Protagonist Therapeutics?
Protagonist Therapeutics all-time high annual cash flow from financing activities is $247.63 M
What is Protagonist Therapeutics annual CFF year-on-year change?
Over the past year, PTGX annual cash flow from financing activities has changed by -$144.62 M (-84.83%)
What is Protagonist Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of PTGX is $4.03 M
What is the all time high quarterly CFF for Protagonist Therapeutics?
Protagonist Therapeutics all-time high quarterly cash flow from financing activities is $126.98 M
What is Protagonist Therapeutics quarterly CFF year-on-year change?
Over the past year, PTGX quarterly cash flow from financing activities has changed by -$8.02 M (-66.55%)
What is Protagonist Therapeutics TTM cash flow from financing activities?
The current TTM CFF of PTGX is $25.85 M
What is the all time high TTM CFF for Protagonist Therapeutics?
Protagonist Therapeutics all-time high TTM cash flow from financing activities is $261.02 M
What is Protagonist Therapeutics TTM CFF year-on-year change?
Over the past year, PTGX TTM cash flow from financing activities has changed by +$3.50 M (+15.68%)